Search

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Championing for people with all abilities

Every diverse background brings unique perspectives to our company.

A sense of community and a love for gardening that’s lasted decades at our U.S. headquarters

Discover our longstanding love for gardening and how it started with Schatzi’s chives.

Focus on Alliance Management

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Real-world study shows sequencing of Gilotrif

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

BI USA Recognized as Best Place to Work for LGBTQ+ Equality

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.

Are combination therapies the answer to battling KRAS cancers?

Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Six creative Connecticut students turn aspiring ideas into inventive innovation

Learn about the 2023 Connecticut Invention Convention winners.

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

More Green | Sustainable Development

Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.

How Much Do You Know About PPID? | Boehringer Ingelheim US

Click here to find out more about some of the common misconceptions you might have about pituitary pars intermedia dysfunction (PPID).

Marie Penzold

Marie Penzold talks about her career as a HR business partner in the Innovation unit here at Boehringer Ingelheim.

Our Curiosity Never Stops | Boehringer Ingelheim US

Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.

A Moment To Reflect on the Evolving Approach for Diabetes Management | Boehringer Ingelheim US

A Moment To Reflect on the Evolving Approach for Diabetes Management

US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes

The Importance of Drug Discovery | R&D | Boehringer Ingelheim US

Research & Development

HBA Rising Star & Luminary Awards | Boehringer Ingelheim US

Read more on the HBA, is a global nonprofit organization recognizing outstanding individuals and companies who impact and influence women in healthcare.

Our Culture of Caring: Volunteering

At BI we are committed to improving the health and well-being of people & animals. We encourage & support employee volunteer activities.

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Our Mission

Our Story

Ethics and Compliance

Diversity

At Boeheringer Ingelheim, we believe in a diverse working culture. Find out what our people like most about working with us.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers